Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Human Insulin Clear all
Completed Phase 3 Interventional

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

NCT00127634
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 7:30 AM EDT
Completed No phase listed Observational

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

NCT00642681
View directory record Official record
Conditions
Diabetes Mellitus, Upper Respiratory Infection
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tuscon, Arizona • Fresno, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

NCT03143816
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Technosphere insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 3, 2026, 7:30 AM EDT
Active, not recruiting No phase listed Observational

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

NCT05757583
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 2 Interventional Results available

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

NCT00754624
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
San Mateo, California • Santa Barbara, California • Middlebury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

NCT00136916
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Therapeutic Choice Questionnaire Study

NCT00139763
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Educational Materials
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
View directory record Official record
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

NCT01786707
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin
Biological · Other · Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
45 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

NCT01902121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin 10U + 20U, Technosphere® Insulin 30U
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Sep 3, 2026, 7:30 AM EDT
Completed No phase listed Observational

Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

NCT02188758
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adults - CFPE Treatment
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
South Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

NCT02642159
View directory record Official record
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Results available

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Dose Titration Study

NCT00246623
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education
Drug · Procedure · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2008 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

NCT00134147
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2008 · Synced Sep 3, 2026, 7:30 AM EDT
Not listed Phase 4 Interventional

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

NCT04125082
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

NCT01982604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TI-Inhalation Powder A, TI-Inhalation Powder B
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909
View directory record Official record
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

NCT00391209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 7:30 AM EDT